On October 19, 2026, Disc Medicine, Inc. announced positive results from its pivotal Phase 3 APOLLO trial of bitopertin, a treatment for erythropoietic protoporphyria (EPP). This announcement is significant as it demonstrates the company's commitment to advancing its product pipeline in the pharmaceutical preparations sector.
Disc Medicine, Inc., trading under the ticker IRON on the Nasdaq, specializes in developing innovative therapies for patients with hematological diseases. The company has undergone several name changes, previously known as Gemini Therapeutics, Inc. and FS Development Corp., reflecting its evolving focus on life sciences.
The SEC filing revealed that the APOLLO trial met all its primary and secondary endpoints, marking a critical milestone for the company. The trial, which involved 183 patients across the U.S., Canada, Europe, and Australia, evaluated the efficacy and safety of bitopertin compared to a placebo. According to the filing, "Bitopertin achieved statistical significance on both co-primary endpoints vs. placebo."
This success could have far-reaching implications for patients suffering from EPP, a rare disease characterized by painful reactions to sunlight. The trial results indicated a significant reduction in whole-blood metal-free protoporphyrin IX levels and an increase in the average monthly time patients could spend in light without pain.
As a result of these findings, Disc Medicine plans to resubmit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) by the end of 2026, with a decision anticipated by mid-2027. This timeline is crucial as it positions the company to potentially bring a much-needed treatment to market, enhancing its competitive edge in the pharmaceutical industry.
The filing does not specify what happens next, but the upcoming NDA resubmission will be a key focus for both the company and industry observers. Competitors in the pharmaceutical preparations space will likely monitor the developments closely, as the successful approval of bitopertin could set a precedent for future treatments targeting rare diseases.